Brain Tumor Clinical Trials

Find Brain Tumor Clinical Trials Near You

Genetic and Molecular Characterization of Nervous System Lesions

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

Primary and secondary brain tumors, the leading cause of death from cancer before the age of 35, represent a complex and heterogeneous group of pathologies with a generally poor prognosis. Knowledge of these tumors has made enormous strides thanks to access to biological samples, leading to a much more robust, reliable and precise histo-pronostic classification, but also, increasingly, to the identification of theranostic targets. Despite these advances, there is a real need to refine diagnostic and prognostic classification, identify the biological mechanisms involved in the formation and progression of these pathologies, develop new targeted strategies, and devise minimally invasive follow-up methods (liquid biopsies). In addition, certain non-tumoral brain lesions (e.g. malformations) can be similarly classified according to their molecular and mutational profile. This project aims to make a decisive contribution to these objectives.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Any patient operated on for a brain lesion (e.g. tumors: glioma, LCPSNC, meningioma, or rare tumor) and/or followed up for one of these pathologies.

• Age ≥ 18 years

• Consent or non-opposition of the patient or his/her legal representative (guardian) to participate in the study.

Locations
Other Locations
France
Service de Neurochirurgie - Hôpital de la Pitié Salpêtrière
RECRUITING
Paris
Service de Neurologie 2 -Hôpital de la Pitié Salpêtrière
RECRUITING
Paris
Service de Radiothérapie - Hôpital de la Pittié Salpêtrière
RECRUITING
Paris
Contact Information
Primary
Marc Sanson, Prof
marc.sanson@aphp.fr
01 42 16 03 91
Time Frame
Start Date: 2024-03-26
Estimated Completion Date: 2034-03
Participants
Target number of participants: 10000
Treatments
Group 1
Patients already included in the first ONCONEUROTEK (retrospective) study and followed up in the participating center : at their next hospitalization or consultation at Pitié Salpêtrière, they will be given an information note and a consent form (NIFC) informing them of the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date \< 2 years)
Group 2
Patients included prospectively : Patients who may be included in this study will be informed of its objectives and procedures by the doctor in charge of their follow-up, during a consultation visit or routine hospitalization, by means of an information note.~(This population concerns around 1,000 patients per year, i.e. around 10,000 patients over 10 years)
Group 3
This group concerns patients already included in the ONCONEUROTEK study (retrospective) but not currently being followed at the Pitié Salpêtrière hospital. Specifically, patients who are known to the investigators to still be alive. In this case, an information note and a non-opposition form (NINO) will be sent to them by mail to :~* inform them of the regulatory update under the Loi Jardé and the RGPD~* and collect their non-opposition to the re-use of their data and samples.~* If no reply is received within one month, the patient will be deemed not to have objected to the re-use of his or her data and samples in the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date \> 2 years)
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov